My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 105

    1.

    5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.

    Von Hoff DD, Slavik M, Muggia FM.

    Ann Intern Med. 1976 Aug;85(2):237-45. Review.PMID: 60073 [PubMed - indexed for MEDLINE]Related articles

    2.

    [Possibilities for the clinical use of 5-azacytidine]

    Veselý J, Cihák A.

    Vopr Onkol. 1977;23(10):65-73. Review. Russian. PMID: 74127 [PubMed - indexed for MEDLINE]Related articles

    3.

    5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia.

    Vogler WR, Miller DS, Keller JW.

    Blood. 1976 Sep;48(3):331-7.PMID: 60156 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    5-azacytidine--a new anticancer drug with significant activity in acute myeloblastic leukemia.

    von Hoff DD, Slavik M.

    Adv Pharmacol Chemother. 1977;14:285-326. Review. No abstract available. PMID: 70163 [PubMed - indexed for MEDLINE]Related articles

    5.

    5-azacytidine in refractory acute leukemia.

    Case DC Jr.

    Oncology. 1982;39(4):218-21.PMID: 6178065 [PubMed - indexed for MEDLINE]Related articles

    6.

    Treatment of acute leukemia with 5-azacytidine (NSC-102816).

    McCredie KB, Bodey GP, Burgess MA, Gutterman JU, Rodriguez V, Sullivan MP, Freireich EJ.

    Cancer Chemother Rep. 1973 Sep-Oct;57(3):319-23. No abstract available. PMID: 4127393 [PubMed - indexed for MEDLINE]Related articles

    7.

    5-Azacytidine: a new active agent for the treatment of acute leukemia.

    Karon M, Sieger L, Leimbrock S, Finklestein JZ, Nesbit ME, Swaney JJ.

    Blood. 1973 Sep;42(3):359-65. No abstract available. PMID: 4125239 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    5-azacytidine in acute leukemia.

    Saiki JH, McCredie KB, Vietti TJ, Hewlett JS, Morrison FS, Costanzi JJ, Stuckey WJ, Whitecar J, Hoogstraten B.

    Cancer. 1978 Nov;42(5):2111-4.PMID: 82472 [PubMed - indexed for MEDLINE]Related articles

    9.

    Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.

    Wilhelm M, O'Brien S, Rios MB, Estey E, Keating MJ, Plunkett W, Sorenson M, Kantarjian HM.

    Leuk Lymphoma. 1999 Aug;34(5-6):511-8.PMID: 10492074 [PubMed - indexed for MEDLINE]Related articles

    10.

    Biological effects of 5-azacytidine in eukaryotes.

    Cihák A.

    Oncology. 1974;30(5):405-22.PMID: 4142650 [PubMed - indexed for MEDLINE]Related articles

    11.

    Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

    Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G.

    Blood. 2007 Oct 1;110(7):2302-8. Epub 2007 Jun 27.PMID: 17596541 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.

    Beran M, Jeha S, O'Brien S, Estey E, Vitek L, Zurlo MG, Rios MB, Keating M, Kantarjian H.

    Clin Cancer Res. 1997 Dec;3(12 Pt 1):2377-84.PMID: 9815637 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.

    Goldberg J, Gryn J, Raza A, Bennett J, Browman G, Bryant J, Grunwald H, Larson R, Vogler R, Preisler H.

    Am J Hematol. 1993 Aug;43(4):286-90.PMID: 7690519 [PubMed - indexed for MEDLINE]Related articles

    14.

    Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.

    Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ.

    Am J Med. 1986 Sep;81(3):387-94.PMID: 3463209 [PubMed - indexed for MEDLINE]Related articles

    15.

    Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

    Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M.

    J Clin Oncol. 2003 Mar 15;21(6):1167-73.PMID: 12637486 [PubMed - indexed for MEDLINE]Related articles

    16.

    High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.

    Van Echo DA, Wiernik PH, Aisner J.

    Cancer Clin Trials. 1980;3(4):325-8.PMID: 6933027 [PubMed - indexed for MEDLINE]Related articles

    17.

    5-azacytidine.

    [No authors listed]

    IARC Monogr Eval Carcinog Risk Chem Hum. 1981 May;26:37-46. No abstract available. PMID: 6168559 [PubMed - indexed for MEDLINE]Related articles

    18.

    [Mechanism of cystostatic effect of 5-azacytidine and its usefulness in clinic]

    Veselý J, Cihák A.

    Cas Lek Cesk. 1975 May 16;114(20):607-11. Czech. No abstract available. PMID: 48423 [PubMed - indexed for MEDLINE]Related articles

    19.

    [Clinical pharmacology of 5-azacytidine]

    Robak T.

    Pol Tyg Lek. 1984 Feb 13;39(7):215-8. Polish. No abstract available. PMID: 6205386 [PubMed - indexed for MEDLINE]Related articles

    20.

    Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.

    Neil GL, Moxley TE, Kuentzel SL, Manak RC, Hanka LJ.

    Cancer Chemother Rep. 1975 May-Jun;59(3):459-65.PMID: 54211 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity